ENOV Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -90.11% compared to Enovis Corp.'s net margin of -13.47%. Enovis Corp.'s return on equity of -52.38% beat Accuray, Inc.'s return on equity of -60.6%.

Enovis Corp. has a consensus price target of $45.18, signalling upside risk potential of 77.39%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 337.23%. Given that Accuray, Inc. has higher upside potential than Enovis Corp., analysts believe Accuray, Inc. is more attractive than Enovis Corp..

Enovis Corp. has a beta of 1.285, which suggesting that the stock is 28.492% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $575.8M, which are larger than Accuray, Inc. quarterly revenues of $102.2M. Enovis Corp.'s net income of -$518.8M is lower than Accuray, Inc.'s net income of -$13.8M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.65x versus 0.15x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integra LifeSciences Holdings Corp. has a net margin of -90.11% compared to Enovis Corp.'s net margin of -0.39%. Enovis Corp.'s return on equity of -52.38% beat Integra LifeSciences Holdings Corp.'s return on equity of -41.72%.

Enovis Corp. has a consensus price target of $45.18, signalling upside risk potential of 77.39%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.13 which suggests that it could grow by 32.91%. Given that Enovis Corp. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Enovis Corp. is more attractive than Integra LifeSciences Holdings Corp..

Enovis Corp. has a beta of 1.285, which suggesting that the stock is 28.492% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.036, suggesting its more volatile than the S&P 500 by 3.641%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $575.8M, which are larger than Integra LifeSciences Holdings Corp. quarterly revenues of $434.9M. Enovis Corp.'s net income of -$518.8M is lower than Integra LifeSciences Holdings Corp.'s net income of -$1.7M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.65x versus 0.53x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -90.11% compared to Enovis Corp.'s net margin of -316.61%. Enovis Corp.'s return on equity of -52.38% beat Plus Therapeutics, Inc.'s return on equity of --.

Enovis Corp. has a consensus price target of $45.18, signalling upside risk potential of 77.39%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Enovis Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Enovis Corp..

Enovis Corp. has a beta of 1.285, which suggesting that the stock is 28.492% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $575.8M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Enovis Corp.'s net income of -$518.8M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.65x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -90.11% compared to Enovis Corp.'s net margin of -29.42%. Enovis Corp.'s return on equity of -52.38% beat Twist Bioscience Corp.'s return on equity of -16.63%.

Enovis Corp. has a consensus price target of $45.18, signalling upside risk potential of 77.39%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could grow by 6.33%. Given that Enovis Corp. has higher upside potential than Twist Bioscience Corp., analysts believe Enovis Corp. is more attractive than Twist Bioscience Corp..

Enovis Corp. has a beta of 1.285, which suggesting that the stock is 28.492% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.240, suggesting its more volatile than the S&P 500 by 124.046%.

Enovis Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis Corp. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Enovis Corp. quarterly revenues are $575.8M, which are larger than Twist Bioscience Corp. quarterly revenues of $103.7M. Enovis Corp.'s net income of -$518.8M is lower than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Enovis Corp.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis Corp. is 0.65x versus 7.26x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.